Nephro-Urology Monthly

Published by: Kowsar

Testosterone Replacement Therapy: Should It Be Performed in Erectile Dysfunction?

Orcun Celik 1 , * and Selcuk Yücel 2
Authors Information
1 Clinic of Urology, Kemalpasa State Hospital, Kemalpasa, Izmir, Turkey
2 Department of Urology, Medical Faculty, Akdeniz University, Antalya, Turkey
Article information
  • Nephro-Urology Monthly: September 01, 2013, 5 (4); 858-861
  • Published Online: July 29, 2013
  • Article Type: Review Article
  • Received: April 11, 2013
  • Accepted: May 22, 2013
  • DOI: 10.5812/numonthly.11523

To Cite: Celik O, Yücel S. Testosterone Replacement Therapy: Should It Be Performed in Erectile Dysfunction?, Nephro-Urol Mon. 2013 ; 5(4):858-861. doi: 10.5812/numonthly.11523.

Copyright © 2013, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Physiology of Testosterone
  • 1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84(1): 50-6[PubMed]
  • 2. Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB, Abdel-Mageed AB, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol. 2003; 169(5): 1911-7[DOI][PubMed]
  • 3. Roumeguere T. Rationale for androgens and erectile dysfunction in 2006. Eur Urol. 2006; 50(5): 898-900[DOI][PubMed]
  • 4. Buvat J, Bou Jaoude G. Significance of hypogonadism in erectile dysfunction. World J Urol. 2006; 24(6): 657-67[DOI][PubMed]
  • 5. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM, et al. Endocrine aspects of sexual dysfunction in men. J Sex M. 2004; 1(1): 69-81
  • 6. Carani C, Bancroft J, Granata A, Del Rio G, Marrama P. Testosterone and erectile function, nocturnal penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal and eugonadal men. Psychoneuroendocrinology. 1992; 17(6): 647-54[PubMed]
  • 7. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999; 140(4): 1861-8[PubMed]
  • 8. Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN, et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl. 2003; 24(3): 381-7[PubMed]
  • 9. Seftel AD. Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol. 2003; 169(6): 1999-2007[DOI][PubMed]
  • 10. Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl. 2005; 26(2): 242-8[PubMed]
  • 11. Traish AM, Kim N. Weapons of penile smooth muscle destruction: androgen deficiency promotes accumulation of adipocytes in the corpus cavernosum. Aging Male. 2005; 8(3-4): 141-6[DOI][PubMed]
  • 12. Armagan A, Kim NN, Goldstein I, Traish AM. Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl. 2006; 27(4): 517-26[DOI][PubMed]
  • 13. Yildiz O, Seyrek M, Irkilata HC, Yildirim I, Tahmaz L, Dayanc M. Testosterone might cause relaxation of human corpus cavernosum by potassium channel opening action. Urology. 2009; 74(1): 229-32[DOI][PubMed]
  • 14. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med. 2005; 2(6): 759-70[DOI][PubMed]
  • 15. Penson DF, Ng C, Cai L, Rajfer J, Gonzalez-Cadavid NF. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod. 1996; 55(3): 567-74[PubMed]
  • 16. Reilly CM, Stopper VS, Mills TM. Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl. 1997; 18(1): 26-31[PubMed]
  • 17. Channer K, Dumas C. Prospective evaluation of the effects of testosterone therapy in hypogonadal men with type 2 diabetes or metabolic syndrome: demographic analysis of TIMES2 study. Diabetes Vasc Dis Res. 2007; 4: 164-8
  • 18. Buvat J. Who would benefit from testosterone therapy? 2009;
  • 19. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med. 2007; 4(2): 497-501[DOI][PubMed]
  • 20. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005; 63(3): 280-93[DOI][PubMed]
  • 21. Palumbo F, Bettocchi C, Selvaggi FP, Pryor JP, Ralph DJ. Sildenafil: efficacy and safety in daily clinical experience. Eur Urol. 2001; 40(2): 176-80[PubMed]
  • 22. Gooren L. The role of testosterone in erectile function and dysfunction. JMHG. 2006; (3): 292-298
  • 23. Chatterjee R, Wood S, McGarrigle HH, Lees WR, Ralph DJ, Neild GH. A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. J Fam Plann Reprod Health Care. 2004; 30(2): 88-90[PubMed]
  • 24. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol. 2005; 173(2): 530-2[DOI][PubMed]
  • 25. Hwang TI, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res. 2006; 18(4): 400-4[DOI][PubMed]
  • 26. Rosenthal BD, May NR, Metro MJ, Harkaway RC, Ginsberg PC. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology. 2006; 67(3): 571-4[DOI][PubMed]
  • 27. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia. 2006; 38(2): 61-8[DOI][PubMed]
  • 28. Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009; 151(9): 650-61[DOI][PubMed]
  • 29. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011; 8(1): 284-93[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments